Why Firefly Neuroscience, Inc.’s (AIFF) Stock Is Down 16.19%
As of Tuesday, February 25, Firefly Neuroscience, Inc.’s AIFF share price has dipped by 16.19%, which has investors questioning if this is right time to buy.Omar Beirat
| SECTOR | INDUSTRY |
| Health Care | Health Care Technology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Omar Beirat
Aneeqa Nadeem
Tudor Pop
Aneeqa Nadeem
Aneeqa Nadeem
| Share Statistics | AIFF | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $14.7 | $330.0 | 9% |
|
| Shares Out (Mil) | 21.6 | 55.3 | 32% |
|
| Institutional Ownership | 62.4% | 79.3% | 39% |
|
| Float (Mil) | 13.4 | 45.0 | 23% |
|
| Beta | na | 1.25 | na |
|
| Avg Daily Volume (000s) | 63 | 395 | 31% |
|
| Price Change (52-week) |
(46.3%) | 63.9% | 22% |
|
| Growth | AIFF | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.5% | na |
|
| Net Income (5yr) | na | 5.4% | na |
|
| EPS (5yr) | na | 15.5% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.5%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AIFF | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $211 | 3% |
|
| Net Income (TTM) (Mil) | ($8) | ($10) | 30% |
|
| EPS (TTM) | ($0.469) | ($0.700) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | $9 | 23% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $3 | 52% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $15 | 0% |
|
| Enterprise Value (Q1) (Mil) | $7 | $195 | 7% |
|
| Valuation | AIFF | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.10 | 1.24 | 30% |
|
| P/E | na | 43.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 2.7 | na |
|
| Ratios | AIFF | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 57.4% | 61.3% | 70% |
|
| Net Margin | (386.2%) | (21.7%) | 2% |
|
| ROA | (57.1%) | (15.6%) | 10% |
|
| ROE | (68.8%) | (15.3%) | 12% |
|
| Liabilities to Assets | 13.1% | 31.4% | 8% |
|
| F-Score | 4 | 4 | 34% |
|
Firefly Neuroscience, Inc. did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors